Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three tricyclic antidepressants (TCAs): amitriptyline, desipramine, and imipramine. All three are small molecule drugs that act primarily by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, thereby increasing their synaptic concentrations. This mechanism enhances mood and can relieve symptoms of depression. Each component has additional pharmacological effects due to interactions with other neurotransmitter systems (e.g., histaminergic, cholinergic), contributing to both therapeutic effects and side effect profiles. While each drug is individually approved for depression and other indications such as neuropathic pain or enuresis (imipramine), there is no widely recognized fixed-dose combination product containing all three agents together; this entry describes a hypothetical or compounded mixture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amitriptyline + desipramine + imipramine.